
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics has demonstrated strong momentum with Filspari, reporting a remarkable 37% quarter-over-quarter increase in new patient start forms for the fourth quarter of 2024, indicating robust prescribing activity. The company has revised its total net sales projection for 2025 upward to $339.9 million, reflecting growing confidence in Filspari's potential as it prepares for key regulatory events and market expansions, particularly with FSGS. Additionally, ongoing commercial launches in Europe and the anticipated impact of updated KDIGO guidelines are expected to enhance market opportunities for Filspari, further solidifying positive financial expectations for Travere Therapeutics.
Bears say
The negative outlook on Travere Therapeutics's stock is primarily driven by several key risks that jeopardize the company’s financial performance and growth potential. Firstly, the potential failure to secure regulatory approval for pegtibatinase, along with the possibility of clinical trial failures, raises significant concerns about the viability of its drug pipeline. Additionally, the competitive landscape for commercial products like FILSPARI introduces uncertainty regarding market penetration and profitability, compounded by operational challenges such as the company's voluntary enrollment pause in trials and ongoing needs for additional funding.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares